Abstract
Metastatic melanoma is one of the most intractable tumors, with all current regimens showing limited survival impact. Failure of most agents is attributed to development of therapy resistance. Accumulated evidence points to the apoptotic defect of melanoma cells and the surge of survival signals stimulated by cytotoxic drugs, as a way that tumors circumvent cytotoxic chemotherapy. An overview of inhibitors developed against these growth/survival factors, which are potential partners to be combined with systemic chemotherapy, will be discussed. The escape mechanism from molecular inhibitors also suggests a “vertical” or “horizontal” combination of molecularly targeted therapies. A better understanding of the interactions between simultaneously used regimens and of the rationale for combination therapy will provide new insights to improve survival and quality of life in patients with advanced melanoma.
Keywords: Melanoma, chemotherapy, drug resistance, targeted therapy, radiation, immunotherapy, dacarbazine, dartmouth regimen, biologics, tremelimumab, ipilimumab, BRAF inhibitor PLX4032, tumor cells, cancer therapy, chemotherapeutic agents
Current Molecular Medicine
Title: Resistance to Chemotherapy and Molecularly Targeted Therapies: Rationale for Combination Therapy in Malignant Melanoma
Volume: 11 Issue: 7
Author(s): S. Wu and R.K. Singh
Affiliation:
Keywords: Melanoma, chemotherapy, drug resistance, targeted therapy, radiation, immunotherapy, dacarbazine, dartmouth regimen, biologics, tremelimumab, ipilimumab, BRAF inhibitor PLX4032, tumor cells, cancer therapy, chemotherapeutic agents
Abstract: Metastatic melanoma is one of the most intractable tumors, with all current regimens showing limited survival impact. Failure of most agents is attributed to development of therapy resistance. Accumulated evidence points to the apoptotic defect of melanoma cells and the surge of survival signals stimulated by cytotoxic drugs, as a way that tumors circumvent cytotoxic chemotherapy. An overview of inhibitors developed against these growth/survival factors, which are potential partners to be combined with systemic chemotherapy, will be discussed. The escape mechanism from molecular inhibitors also suggests a “vertical” or “horizontal” combination of molecularly targeted therapies. A better understanding of the interactions between simultaneously used regimens and of the rationale for combination therapy will provide new insights to improve survival and quality of life in patients with advanced melanoma.
Export Options
About this article
Cite this article as:
Wu S. and Singh R.K., Resistance to Chemotherapy and Molecularly Targeted Therapies: Rationale for Combination Therapy in Malignant Melanoma, Current Molecular Medicine 2011; 11 (7) . https://dx.doi.org/10.2174/156652411800615153
DOI https://dx.doi.org/10.2174/156652411800615153 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Candidate Genes for Lack of Sensitivity to Therapy in Pediatric Leukemias
Current Cancer Drug Targets Nerve Growth Factor Receptors and Signaling in Breast Cancer
Current Cancer Drug Targets Oxidative Phosphorylation as a Target to Arrest Malignant Neoplasias
Current Medicinal Chemistry Identification and Targeting of Tumor Escape Mechanisms: A New Hope for Cancer Therapy?
Current Pharmaceutical Design Strategies for Stalling Malignancy: Targeting Cancers Addiction to Hsp90
Current Topics in Medicinal Chemistry In Vivo DNA Electrotransfer for Immunotherapy of Cancer and Neurodegenerative Diseases
Current Drug Metabolism Detection of Cancer Cells on a Chip
Current Topics in Medicinal Chemistry Intrinsic Disorder in Male Sex Determination: Disorderedness of Proteins from the Sry Transcriptional Network
Current Protein & Peptide Science Prevention of Allergic Disease Development and Symptoms by Food Factors
Current Pharmaceutical Design Isoprenylation of Intracellular Proteins as a New Target for the Therapy of Human Neoplasms: Preclinical and Clinical Implications
Current Drug Targets Mapping the High Throughput SEREX Technology Screening for Novel Tumor Antigens
Combinatorial Chemistry & High Throughput Screening Toxicity of Magnetic Resonance Imaging Agents: Small Molecule and Nanoparticle
Current Topics in Medicinal Chemistry Drug Delivery Systems for Brain Tumor Therapy
Current Pharmaceutical Design Molecular Docking of 4-ethoxychalcones on Oxidoreductase/Pirin Inhibitors and Cytotoxic Evaluation on Breast/Skin Cancer Cell Lines
Letters in Drug Design & Discovery New Entrants into Clinical Trials for Targeted Therapy of Breast Cancer: An Insight
Anti-Cancer Agents in Medicinal Chemistry Plant Polyphenols: Natural and Potent UV-Protective Agents for the Prevention and Treatment of Skin Disorders
Mini-Reviews in Medicinal Chemistry Anti-Cancer Agent-Induced Nephrotoxicity
Anti-Cancer Agents in Medicinal Chemistry A Concise Review of Current Radiopharmaceuticals in Tumor Angiogenesis Imaging
Current Pharmaceutical Design The Antisense Oligonucleotide Trabedersen (AP 12009) for the Targeted Inhibition of TGF-β2
Current Pharmaceutical Biotechnology Nanosystems in Drug Targeting: Opportunities and Challenges
Current Nanoscience